Does the media refer more to ETON or AMRX?

In the previous week, Eton Pharmaceuticals had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 9 mentions for Eton Pharmaceuticals and 4 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.90 beat Eton Pharmaceuticals' score of 0.87 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ETON or LQDA?

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Liquidia. MarketBeat recorded 9 mentions for Eton Pharmaceuticals and 8 mentions for Liquidia. Eton Pharmaceuticals' average media sentiment score of 0.87 beat Liquidia's score of 0.72 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DFTX or ETON?

In the previous week, Definium Therapeutics had 8 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 17 mentions for Definium Therapeutics and 9 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.87 beat Definium Therapeutics' score of 0.33 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Eton Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MANE or ETON?

In the previous week, Eton Pharmaceuticals had 8 more articles in the media than Veradermics. MarketBeat recorded 9 mentions for Eton Pharmaceuticals and 1 mentions for Veradermics. Eton Pharmaceuticals' average media sentiment score of 0.87 beat Veradermics' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INDV or ETON?

In the previous week, Eton Pharmaceuticals had 5 more articles in the media than Indivior. MarketBeat recorded 9 mentions for Eton Pharmaceuticals and 4 mentions for Indivior. Eton Pharmaceuticals' average media sentiment score of 0.87 beat Indivior's score of 0.46 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eton Pharmaceuticals (ETON) Competitors

$59.19 +0.01 (+0.02%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$59.90 +0.71 (+1.20%)

As of 07:30 AM Eastern

Compare

ETON vs. AMRX, LQDA, DFTX, MANE, and INDV

Should you buy Eton Pharmaceuticals stock or one of its competitors? Eton Pharmaceuticals's main competitors and comparable companies include Amneal Pharmaceuticals (AMRX), Liquidia (LQDA), Definium Therapeutics (DFTX), Veradermics (MANE), and Indivior (INDV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

In the previous week, Eton Pharmaceuticals had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 9 mentions for Eton Pharmaceuticals and 4 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.90 beat Eton Pharmaceuticals' score of 0.87 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals presently has a consensus price target of $67.50, suggesting a potential upside of 14.04%. Amneal Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 3.96%. Given Eton Pharmaceuticals' higher probable upside, equities analysts plainly believe Eton Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Eton Pharmaceuticals has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Amneal Pharmaceuticals has higher revenue and earnings than Eton Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$105.60M	16.02	-$4.60M	$0.38	155.76
Amneal Pharmaceuticals	$3.02B	2.14	$72.06M	$0.49	41.22

Eton Pharmaceuticals has a net margin of 12.02% compared to Amneal Pharmaceuticals' net margin of 5.05%. Eton Pharmaceuticals' return on equity of 40.13% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Summary

Amneal Pharmaceuticals beats Eton Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Liquidia?

Eton Pharmaceuticals (NASDAQ:ETON) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Eton Pharmaceuticals has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Eton Pharmaceuticals has higher earnings, but lower revenue than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$105.60M	16.02	-$4.60M	$0.38	155.76
Liquidia	$450.91M	14.03	-$68.92M	$1.37	51.60

Liquidia has a net margin of 30.74% compared to Eton Pharmaceuticals' net margin of 12.02%. Liquidia's return on equity of 149.65% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Liquidia	30.74%	149.65%	36.30%

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Eton Pharmaceuticals presently has a consensus target price of $67.50, suggesting a potential upside of 14.04%. Liquidia has a consensus target price of $98.08, suggesting a potential upside of 38.75%. Given Liquidia's higher possible upside, analysts clearly believe Liquidia is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Liquidia. MarketBeat recorded 9 mentions for Eton Pharmaceuticals and 8 mentions for Liquidia. Eton Pharmaceuticals' average media sentiment score of 0.87 beat Liquidia's score of 0.72 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Liquidia beats Eton Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Eton Pharmaceuticals has a net margin of 12.02% compared to Definium Therapeutics' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Definium Therapeutics currently has a consensus price target of $64.88, suggesting a potential upside of 69.79%. Eton Pharmaceuticals has a consensus price target of $67.50, suggesting a potential upside of 14.04%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Definium Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
Eton Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Definium Therapeutics had 8 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 17 mentions for Definium Therapeutics and 9 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.87 beat Definium Therapeutics' score of 0.33 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Eton Pharmaceuticals	$105.60M	16.02	-$4.60M	$0.38	155.76

Definium Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Summary

Eton Pharmaceuticals beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Veradermics?

Veradermics (NYSE:MANE) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Eton Pharmaceuticals has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Eton Pharmaceuticals	$105.60M	16.02	-$4.60M	$0.38	155.76

In the previous week, Eton Pharmaceuticals had 8 more articles in the media than Veradermics. MarketBeat recorded 9 mentions for Eton Pharmaceuticals and 1 mentions for Veradermics. Eton Pharmaceuticals' average media sentiment score of 0.87 beat Veradermics' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics currently has a consensus price target of $153.00, indicating a potential upside of 30.22%. Eton Pharmaceuticals has a consensus price target of $67.50, indicating a potential upside of 14.04%. Given Veradermics' higher possible upside, research analysts clearly believe Veradermics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eton Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Eton Pharmaceuticals has a net margin of 12.02% compared to Veradermics' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Eton Pharmaceuticals	12.02%	40.13%	12.37%

27.9% of Eton Pharmaceuticals shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Eton Pharmaceuticals beats Veradermics on 11 of the 13 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Indivior?

Indivior (NASDAQ:INDV) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Indivior has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

60.3% of Indivior shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Indivior has a net margin of 26.65% compared to Eton Pharmaceuticals' net margin of 12.02%. Eton Pharmaceuticals' return on equity of 40.13% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Indivior has higher revenue and earnings than Eton Pharmaceuticals. Indivior is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.49	$210M	$2.79	13.11
Eton Pharmaceuticals	$105.60M	16.02	-$4.60M	$0.38	155.76

Indivior currently has a consensus price target of $45.17, suggesting a potential upside of 23.44%. Eton Pharmaceuticals has a consensus price target of $67.50, suggesting a potential upside of 14.04%. Given Indivior's stronger consensus rating and higher probable upside, equities analysts plainly believe Indivior is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Eton Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Eton Pharmaceuticals had 5 more articles in the media than Indivior. MarketBeat recorded 9 mentions for Eton Pharmaceuticals and 4 mentions for Indivior. Eton Pharmaceuticals' average media sentiment score of 0.87 beat Indivior's score of 0.46 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Indivior beats Eton Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Eton Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ETON vs. The Competition

Export

Metric	Eton Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.69B	$12.69B	$7.34B	$13.04B
Dividend Yield	N/A	2.62%	2.52%	14.18%
P/E Ratio	155.76	787.37	273.78	25.68
Price / Sales	16.02	833.31	616.14	75.92
Price / Cash	11,417.66	91.32	80.06	52.35
Price / Book	60.40	10.61	10.41	6.34
Net Income	-$4.60M	$2.83B	$3.50B	$360.56M
7 Day Performance	6.44%	-1.13%	-1.41%	-1.60%
1 Month Performance	-0.99%	-1.37%	-4.16%	-4.10%
1 Year Performance	172.39%	0.33%	12.62%	3.79%

Eton Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ETON Eton Pharmaceuticals	3.9071 of 5 stars	$59.19 +0.0%	$67.50 +14.0%	+163.3%	$1.69B	$105.60M	155.76	44	News Coverage Positive News
AMRX Amneal Pharmaceuticals	2.7938 of 5 stars	$19.53 -3.1%	$20.14 +3.2%	+104.7%	$6.27B	$3.02B	40.06	8,500
LQDA Liquidia	3.6179 of 5 stars	$67.38 +1.4%	$98.08 +45.6%	+210.0%	$6.02B	$158.32M	49.09	216
DFTX Definium Therapeutics	3.054 of 5 stars	$39.37 +0.2%	$64.88 +64.8%	+217.4%	$5.29B	N/A	N/A	40	Trending News Insider Trade
MANE Veradermics	1.9833 of 5 stars	$119.21 +5.7%	$153.00 +28.3%	N/A	$4.98B	N/A	N/A	21

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ETON) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Competitors

ETON vs. AMRX, LQDA, DFTX, MANE, and INDV

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does Eton Pharmaceuticals compare to Liquidia?

Summary

How does Eton Pharmaceuticals compare to Definium Therapeutics?

Summary

How does Eton Pharmaceuticals compare to Veradermics?

Summary

How does Eton Pharmaceuticals compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Competitors

ETON vs. AMRX, LQDA, DFTX, MANE, and INDV

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Does the media refer more to ETON or AMRX?

Do analysts prefer ETON or AMRX?

Which has more risk and volatility, ETON or AMRX?

Do institutionals & insiders hold more shares of ETON or AMRX?

Which has stronger valuation & earnings, ETON or AMRX?

Is ETON or AMRX more profitable?

Summary

How does Eton Pharmaceuticals compare to Liquidia?

Which has more risk and volatility, ETON or LQDA?

Which has higher valuation and earnings, ETON or LQDA?

Is ETON or LQDA more profitable?

Do insiders & institutionals have more ownership in ETON or LQDA?

Do analysts rate ETON or LQDA?

Does the media favor ETON or LQDA?

Summary

How does Eton Pharmaceuticals compare to Definium Therapeutics?

Is DFTX or ETON more profitable?

Do insiders and institutionals hold more shares of DFTX or ETON?

Do analysts prefer DFTX or ETON?

Does the media refer more to DFTX or ETON?

Which has preferable earnings and valuation, DFTX or ETON?

Which has more risk and volatility, DFTX or ETON?

Summary

How does Eton Pharmaceuticals compare to Veradermics?

Which has preferable valuation & earnings, MANE or ETON?

Does the media favor MANE or ETON?

Do analysts recommend MANE or ETON?

Is MANE or ETON more profitable?

Do insiders & institutionals have more ownership in MANE or ETON?

Summary

How does Eton Pharmaceuticals compare to Indivior?

Which has more risk & volatility, INDV or ETON?

Do insiders and institutionals hold more shares of INDV or ETON?

Is INDV or ETON more profitable?

Which has higher valuation & earnings, INDV or ETON?

Do analysts rate INDV or ETON?

Does the media favor INDV or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools